Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Revenues

Microsoft Excel

Revenues as Reported

Gilead Sciences Inc., income statement, revenues

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
HIV 19,612 18,175 17,194 16,315 16,938
Liver Disease 3,021 2,784 2,798 2,850 2,924
Veklury 1,799 2,184 3,905 5,565 2,811
Cell Therapy 1,974 1,869 1,459 871 607
Trodelvy 1,315 1,063 680 380 49
Oncology 3,289 2,932 2,139 1,251 656
Other 889 859 946 1,027 1,026
Product sales 28,610 26,934 26,982 27,008 24,355

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Item Description The company
Product sales Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Gilead Sciences Inc. product sales decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.